Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer

Journal of Clinical Pathology - Molecular Pathology

Volumn 55, Issue 5, 2002, Pages 305-309

  Jongsma, A P M ^a   Kenemans, P ^a   Piek, J M J ^a   Zweemer, R P ^a   Verheijen, R H M ^a   Klein Gebbinck, J W T ^a   Van Kamp, G J ^b   Jacobs, I J ^c   Shaw, P ^d   Van Diest, P J ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 13; CHROMOSOME 13Q; CLINICAL ARTICLE; FAMILIAL CANCER; FEMALE; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; ONCOGENE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERINE TUBE CARCINOMA;

CHROMOSOMES, HUMAN, PAIR 13; DNA, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 0036799885     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.55.5.305     Document Type: Article

References (44)

1. Zweemer RP, Verheijen RHM, Gille JJP, et al. Clinical and genetic evaluation of 30 ovarian cancer families. Am J Obstet Gynecol 1998;178:85-90.
2. Zweemer RP, Verheijen RHM, Menko FH, et al. Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol 1999;82:151-3.
3. Zweemer RP, Verheijen RH, Coebergh JW, et al. Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol 2001;98:219-23.
4. Wright K, Wilson PJ, Kerr J, et al. Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene 1998;17:1185-8.
5. Shelling AN, Cooke IE, Ganesan TS. The genetic analysis of ovarian cancer. Br J Cancer 1995;72:521-7.
6. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
7. Casey G. The BRCA1 and BRCA2 breast cancer genes. Curr Opin Oncol 1997;9:88-93.
8. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75.
9. Feunteun J. Breast cancer and genetic instability: the molecules behind the scenes. Mol Med Today 1998;4:263-7.
10. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997;64:196-206.
11. Zweemer RP, Shaw PA, Verheijen RM, et al. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol 1999;52:372-5.
12. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71.
13. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi jews. N Engl J Med 1997;336:1401-8.
14. Woolas RP, Smith JHF, Sarharnis P, et al. Fallopian tube carcinoma: an under-recognized primary neoplasm. Int J Gynaecol Cancer 1997;7:284-8.
15. Piek JMJ, Van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6.
16. Piek JM, van Diest PJ, Zweemer RP, et al. Tubal ligation and risk of ovarian cancer. Lancet 2001;358:844.
17. Zweemer RP, van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45-50.
18. Lakhani SR. Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. Mol Pathol 2001;54:281-4.
19. Vaziri SA, Tubbs RR, Darlington G, et al. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 2001;54:259-63.
20. Duncan JA, Reeves JR, Cooke TG. BRCA1 and BRCA2 proteins: roles in health and disease. Mol Pathol 1998;51:237-47.
21. Knudson AG. All in the (cancer) family [news]. Nat Genet 1993;5:103-4.
22. Ponzone R, Baum M. The BRCA paradox in breast and ovarian cancer. Eur J Cancer 1988;34:966-7.
23. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997;386:761-3.
24. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996;122:135-40.
25. Sato T, Akiyama F, Sakamoto G, et al. Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res 1991;51:5794-9.
26. Yang-Feng TL, Li S, Han H, et al. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer. Int J Cancer 1992;52:575-80.
27. Kim TM, Benedict WF, Xu H-J, et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res 1994;54:605-9.
28. Zweemer RP, Ryan A, Snijders AM, et al. Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest 2001;81:1363-70.
29. Dodson MK, Hartmann LC, Cliby WA, et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res 1993;53:4456-60.
30. Kainu T, Juo SH, Desper R, et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A 2000;97:9603-8.
31. Cliby WA, Ritland SR, Hartmann L, et al. Human epithelial ovarian cancer allelotype. Cancer Res 1993;53:2393-8.
32. Cheng PC, Gosewehr J, Kim TM, et al. Potential role of the inactivated x chromosome in ovarian epithelial tumor development. J Natl Cancer Inst 1996;88:510-18.
33. Li S, Schwartz PE, Lee W-H, et al. Allele loss at the retinoblastoma locus in human ovarian cancer. J Natl Cancer Inst 1991;84:637-40.
34. Karlan BY, Krakow D. Genetic aspects of ovarian cancer. Curr Opin Obstet Gynecol 1994;6:105-10.
35. Pejovic T. Genetic changes in ovarian cancer. Ann Med 1995;27:73-8.
36. Balaban G, Gilbert F, Nichols W, et al. Abnormalities of chromosome #13 in retinoblastomas from individuals with normal constitutional karyotypes. Cancer Genet Cytogenet 1982;6:213-21.
37. Sparkes RS, Murphree AL, Lingua RW, et al. Gene for hereditary retinoblastoma assigned to human chromosome 13 by linkage to esterase D. Science 1983;219:971-3.
38. Strong LC, Riccardi VM, Ferrell RE, et al. Familial retinoblastoma and chromosome 13 deletion transmitted via an insertional translocation. Science 1981;213:1501-3.
39. Sasano H, Comerford J, Silverberg SG, et al. An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer 1990;66:2150-4.
40. Liu Y, Heyman M, Wang Y, et al. Molecular analysis of the retinoblastoma gene in primary ovarian cancer cells. Int J Cancer 1994;58:663-7.
41. Kerangueven F, Noguchi T, Coulier F, et al. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res 1997;57:5469-74.
42. Hagmann. New model for hereditary breast cancer. Science 1999;284:723-3.
43. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
44. Snijders AM, Brakenhoff RH, Van den Brule AJC, et al. Microarray techniques in pathology: tool or toy? Mol Pathol 2000;53;289-94.